NCT04762628View on ClinicalTrials.gov

Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients

NACompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

July 5, 2021

Study Completion Date

August 6, 2021

Conditions
Covid19
Interventions
DIETARY_SUPPLEMENT

MAF capsules 148 mg

enteric capsules based on enzymatically treated bovine colostrum

DIETARY_SUPPLEMENT

M capsules 148 mg

enteric capsules based on enzymatically treated bovine whey

OTHER

Standard of care

Standard of care

Trial Locations (2)

61000

Municipal Kharkiv Regional Infectious Diseases Clinical Hospital, Kharkiv

93012

The Central Hospital of Rubizhne, Infection Disease Department, Rubizhne

All Listed Sponsors
lead

Saisei Pharma

INDUSTRY

NCT04762628 - Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients | Biotech Hunter | Biotech Hunter